In March 2025, Japan’s Ministry of Health, Labour and Welfare has approved the marketing and manufacturing of Dupixent ...

Time magazine is spotlighting key players in the artificial intelligence revolution for its 2025 Person of the Year, the magazine announced Thursday. "The architects of AI" are the latest recipients ...

Emphysema detected on baseline low-dose chest CT (LDCT) in the lung cancer screening cohort of more than 9,000 asymptomatic adults was associated with death from all causes, chronic obstructive ...

Visually assessed pulmonary emphysema independently predicted modestly elevated all-cause mortality risk over 25 years of follow-up in patients with a history of smoking. After controlling for other ...

Emphysema detected on baseline low-dose chest CT (LDCT) in the lung cancer screening cohort of more than 9,000 asymptomatic adults was associated with death from all causes, chronic obstructive ...

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken a hit after the anti-ST2 monoclonal antibody failed to reduce flare-ups in ...

Emphysematous changes refer to changes that may occur in the lungs as emphysema progresses and are visible on a CT scan. This may include changes in location or the type of damage in the lungs due to ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the Regeneron-partnered drug failed one of a pair of phase 3 chronic obstructive pulmonary ...

Chronic obstructive pulmonary disease, or COPD, is an ongoing group of lung conditions that include chronic bronchitis and emphysema. COPD is the result of damaged lung tissue, which leads to ...

On Thursday, TIME will announce the 2024 Person of the Year. Since 1927, TIME has named a person, group, or concept that had the biggest impact—for good or for ill—on the world over the previous 12 ...

Mona Bafadhel receives funding from the National Institute of Health Research, Asthma+Lung UK, and Horizon Europe. For this study, Mona Bafadhel received funding from AstraZeneca to complete the study ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with the progressive disease suddenly have two new options, with more likely on ...